The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults.
Background: Streptococcus pneumoniae (pneumococcus) remains an important cause of morbidity and mortality. Pneumococcal vaccination is part of the South African pediatric public immunization program but the potential cost-effectiveness of such an intervention for adults is unknown. This study aimed to compare the cost-effectiveness of two widely used pneumococcal vaccines: pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23) in South African adults, 18 years and older.
Author List: Feldman C, Dlamini SK, Madhi SA, Meiring S, von Gottberg A, de Beer JC, de Necker M, Stander MP.
Journal Name: PLoS One. 2020 Jan 29;15(1):e0227945. doi: 10.1371/journal.pone.0227945. PMID: 31995597; PMCID: PMC6988977.